Vedolizumab

维得利珠单抗

Report date: 2026/04/29 20:02:18

Base Information

Drug NameVedolizumab
Drug Alias NameVedolizumabum维多利珠单抗维多珠单抗安吉优Entyvio +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsMucosal addressin cell adhesion molecule-1 inhibitors
TargetsIntegrin alpha-4/beta-7Mucosal addressin cell adhesion molecule-1
Therapy Area/IndicationsPediatric ulcerative colitisSolid tumoursCeliac Disease +[17] 
Global Approved IndicationsCrohn DiseaseColitis, Ulcerative
Approved Indications in ChinaCrohn DiseaseColitis, Ulcerative
Original Approved Country/TerritoryUnited States
Original Approved Date2014/05/20
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdCheo Research InstituteTakeda Pharmaceuticals USA Inc +[9] 
Inactive CompaniesYonsei UniversityMillennium Pharmaceuticals IncTakeda Austria Gmbh +[8] 
Active IndicationsPediatric ulcerative colitisSolid tumoursCrohn Disease +[13] 
Inactive IndicationsCeliac DiseaseInflammatory Bowel DiseasesCholangitis, Sclerosing +[4] 

Other Information

ATC CodeL04AG05
Related LinksWikipediaDrugBankKEGG